Propofol as a substitute for amobarbital in Wada testing

J Clin Neurosci. 2015 Nov;22(11):1830-2. doi: 10.1016/j.jocn.2015.04.014. Epub 2015 Jul 15.

Abstract

We describe a patient with equivocal findings on functional MRI (fMRI), who underwent a propofol Wada test, review the literature on this topic and suggest a protocol for the use of propofol for a Wada test. Although fMRI techniques can usually accurately lateralize language, the Wada test remains the gold standard for preoperative lateralization and is occasionally still required if there are non-diagnostic findings on fMRI. Amobarbital, the agent of choice for the Wada test, has become increasingly difficult to obtain and requires regulatory approval, which may delay definitive management and have an impact on patient outcomes. Propofol has been suggested as an alternative to amobarbital, and while there is some published data on this, there is no reported Australian experience to date.

Keywords: Amobarbital; Interventional neuroradiology; Neoplasm; Propofol; Seizures; Sodium amytal; Wada.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Amobarbital / therapeutic use
  • Australia
  • Brain Neoplasms / surgery
  • Craniotomy / methods*
  • Electroencephalography / drug effects
  • Female
  • Humans
  • Hypnotics and Sedatives / therapeutic use*
  • Intraoperative Neurophysiological Monitoring / methods*
  • Language Tests*
  • Magnetic Resonance Imaging
  • Neuronavigation / methods
  • Propofol / therapeutic use*
  • Wakefulness
  • Young Adult

Substances

  • Hypnotics and Sedatives
  • Amobarbital
  • Propofol